Tahareni Bwanaali, Lena Matata, Laura Hammitt, Patricia Njuguna, Edna Ogada, Nobert Peshu, Angela Karani, Salim Mwarumba, P Ayieko, Antony Etyang, Eric Bunyasi, B Kulohoma, Kenneth Munge, T Kamau, Shanaaz Sharif, Benjamin Tsofa, E Mumbo,Ulla Griffith, Angela Brueggemann, Prof David Goldblatt, Mike English
The Pneumococcal Conjugate Vaccine Impact Study (PCVIS) is a large-scale before-after study of the effectiveness of the 10-valent pneumococcal conjugate vaccine (PCV10) in the routine childhood immunisation schedule in Kenya. The project will compare the incidence rates of invasive pneumococcal disease, radiologically proven pneumonia, and all-cause admissions to hospital in the period before vaccine introduction and the period after vaccine introduction taking account of secular trends in major confounders including HIV, malnutrition, malaria and bed net use.
The project is restricted to the residents of the Kilifi Health and Demographic Surveillance System (KHDSS) and the endpoint events will be defined among admissions to Kilifi District Hospital. PCV10 was introduced into Kilifi District in January 2011.
To measure the total change in IPD incidence and hospital burden following programmatic introduction of 10-valent PCV and to establish a system of longitudinal IPD surveillance to detect serotype replacement disease.
This project proposes to evaluate the total impact of PCV use in children on IPD of both vaccine and non-vaccine types, and intends to disentangle direct from indirect effects by monitoring all individuals in a defined population (the Kilifi DSS) for both immunization events and morbidity events. It aims to define impact in terms of invasive pneumococcal disease but also in terms of more accessible public health end-points such as radiologically-confirmed pneumonia and all admissions to hospital.
The study is a collaborative project with the Division of Vaccines and
Immunization and the results are expected to be used directly by DVI to
determine future vaccine policy.